Showing results (191-200 of 255) with videos related to
Sort By:
Pageof 26
European Heart Journal|March 24, 2022
Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trialScott D Solomon, Brian L Claggett, Zi Michael Miao, et al.Circulation. Heart Failure|December 5, 2025
Efficacy and Safety of Aficamten in Children and Adolescents With Obstructive Hypertrophic Cardiomyopathy: Study Design and Rationale of CEDAR-HCMJuan Pablo Kaski, Paul F Kantor, Stephanie J Nakano, et al.JAMA Cardiology|October 13, 2021
Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure: A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical TrialG Michael Felker, Scott D Solomon, Brian Claggett, et al.Neurology|September 19, 2008
Neurodegeneration associated with genetic defects in phospholipase A(2)A Gregory, S K Westaway, I E Holm, et al.European Heart Journal|June 8, 2022
Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trialMarco Metra, Matteo Pagnesi, Brian L Claggett, et al.ACS Medicinal Chemistry Letters|April 20, 2018
Discovery of <i>Tirasemtiv</i>, the First Direct Fast Skeletal Muscle Troponin ActivatorScott E Collibee, Gustave Bergnes, Alexander Muci, et al.Journal of Cardiac Failure|January 12, 2024
Cardiac Troponin and Treatment Effects of Omecamtiv Mecarbil: Results From the GALACTIC-HF StudyG Michael Felker, Scott D Solomon, Marco Metra, et al.Lancet (London, England)|December 5, 2016
Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trialJohn R Teerlink, G Michael Felker, John J V McMurray, et al.Journal of the American College of Cardiology|September 1, 2024
Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCMCharles F Sherrod, Sara Saberi, Michael E Nassif, et al.Circulation|September 5, 2025
Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM TrialJoseph Campain, Catharine Griskowitz, Chloe Newlands, et al.Pageof 26